Free Trial

Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology logo
$9.01 +0.04 (+0.45%)
(As of 12/20/2024 05:31 PM ET)

Kura Oncology - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
9

Based on 10 Wall Street analysts who have issued ratings for Kura Oncology in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 1 has given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for KURA.

Consensus Price Target

$29.86
231.38% Upside
According to the 10 analysts' twelve-month price targets for Kura Oncology, the average price target is $29.86. The highest price target for KURA is $37.00, while the lowest price target for KURA is $19.00. The average price target represents a forecasted upside of 231.38% from the current price of $9.01.
Get the Latest News and Ratings for KURA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Kura Oncology and its competitors.

Sign Up

KURA Analyst Ratings Over Time

TypeCurrent Forecast
12/24/23 to 12/23/24
1 Month Ago
11/24/23 to 11/23/24
3 Months Ago
9/25/23 to 9/24/24
1 Year Ago
12/24/22 to 12/24/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
9 Buy rating(s)
6 Buy rating(s)
9 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$29.86$29.38$30.60$27.17
Forecasted Upside231.38% Upside171.99% Upside54.39% Upside98.44% Upside
Consensus Rating
Buy
Buy
Buy
Moderate Buy

KURA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KURA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Kura Oncology Stock vs. The Competition

TypeKura OncologyMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside231.38% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent KURA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/9/2024Cantor Fitzgerald
4 of 5 stars
 Reiterated RatingOverweight ➝ Overweight
11/22/2024Bank of America
3 of 5 stars
 Lower TargetBuy ➝ Buy$36.00 ➝ $29.00+189.97%
11/21/2024TD Cowen
5 of 5 stars
 Reiterated RatingBuy
11/21/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$32.00 ➝ $28.00+139.73%
11/21/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$32.00 ➝ $37.00+132.56%
11/19/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$32.00 ➝ $32.00+94.17%
11/4/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$37.00+107.75%
10/24/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Dai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$27.00+58.64%
10/22/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Zhu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/14/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$26.00 ➝ $19.00+2.26%
12/22/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$26.00+106.84%
7/27/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Perform$10.50+5.85%
7/14/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
5/16/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$31.00+147.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:35 AM ET.


KURA Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Kura Oncology is $29.86, with a high forecast of $37.00 and a low forecast of $19.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There is currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KURA shares.

According to analysts, Kura Oncology's stock has a predicted upside of 231.38% based on their 12-month stock forecasts.

Over the previous 90 days, Kura Oncology's stock had 1 upgrade and 1 downgrade by analysts.

Kura Oncology has been rated by research analysts at Bank of America, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, JMP Securities, Lifesci Capital, Stifel Nicolaus, TD Cowen, UBS Group, and Wedbush in the past 90 days.

Analysts like Kura Oncology more than other "medical" companies. The consensus rating for Kura Oncology is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how KURA compares to other companies.


This page (NASDAQ:KURA) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners